13F-HR filed by SR One Capital Management, LP
SR One Capital Management, LP filed this 13F-HR for the quarter ended 2024-06-30, filed 2024-08-13, with 9 holding rows worth $319,401,842.
- Accession
- 0000950123-24-008225
- Filer
- CIK 1910264
- Filed
- 2024-08-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2024
A holdings report, 9 entries on the cover page, a total value of $319,401,842 stated on the cover page (in dollars after the unit check, H1), rows summing to $319,401,842 with VALUE read as dollars as filed, 13F file number 028-21964. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 2,346,630 | $129,510,510 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 1,048,951 | $56,653,844 | dollars as filed | |
| ARS PHARMACEUTICALS INC | 82835W108 | COM | 4,012,903 | $34,149,805 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 1,959,896 | $26,066,617 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 2,016,822 | $23,596,817 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 6,526,476 | $21,863,695 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,333,333 | $19,699,998 | dollars as filed | |
| ENGENE HOLDINGS INC | 29286M105 | COM | 500,000 | $4,715,000 | dollars as filed | |
| KALA BIO INC | 483119202 | COM NEW | 443,661 | $3,145,556 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-24-008225 | this filing | 2024-08-13 | acceptance time not in the bulk data set |